Best Peptides for Anti-Aging — Evidence Review
"Anti-aging" is the broadest peptide-marketing category and the one with the largest gap between claims and evidence. This guide reviews the peptides with documented age-related effects in specific…
"Anti-aging" is the broadest peptide-marketing category and the one with the largest gap between claims and evidence. This guide reviews the peptides with documented age-related effects in specific domains (skin, GH replacement, mitochondrial function) and is honest about the longevity claims that lack human data.
Peptides with documented age-relevant evidence
GHK-Cu (Copper Tripeptide-1) — skin specifically
The most-studied anti-aging peptide topically. Multiple human studies on reduced wrinkle depth, improved elasticity, and skin-smoothing effects with topical application. Mechanism includes copper-mediated growth-factor signaling.
Important constraint: GHK-Cu evidence is strongest topically for skin. Injectable use for systemic anti-aging effects has weaker support.
Sermorelin — adult GH deficiency
GHRH analog used clinically for adult growth hormone deficiency. Reasonable case for use in age-related GH decline where labs document deficiency. Lower magnitude effect than direct GH replacement; safer profile.
The evidence base is for clinically diagnosed deficiency, not for healthy adults seeking general "longevity" benefit. The latter case is poorly supported.
MOTS-c — mitochondrial function
Mitochondrial-derived peptide with insulin-sensitizing and AMPK-activating action in animal models. Plasma levels decline with age. Synthetic analog (MB-4343) cleared a Phase 1 safety study. Human longevity-outcome data does not yet exist; the case is mechanistic.
Tesamorelin — visceral adipose
Reduces visceral adipose tissue, which is metabolically active and inflammatory. Visceral-fat reduction is a meaningful longevity-relevant outcome — but tesamorelin's evidence is from HIV-associated lipodystrophy populations, not general aging.
Claims that outpace evidence
Epitalon
The Khavinson-program longevity-research peptide with the largest gap between published volume and Western verification. Multiple Russian-program studies report telomerase induction, mortality-reduction in elderly cohorts, and gene-regulatory effects. Independent Western replication is essentially absent. The trial designs do not meet modern blinding and central-randomization standards.
We mention epitalon because it dominates anti-aging community discussion. The evidence does not match the marketing claims.
FOXO4-DRI
The senolytic peptide that became famous from a single 2017 mouse paper showing rejuvenation imagery. Zero human clinical trials. The mouse data is interesting but has not progressed to human safety or efficacy testing in the years since.
Humanin and SS-31
Mitochondrial peptides with research interest. Human longevity data does not yet exist.
Full humanin profile → | Full SS-31 profile →
What the evidence does not support
- Any peptide as a "lifespan extender" in humans (no peptide has demonstrated this in any controlled human trial)
- Epitalon as having Western-replicated gene-regulatory effects
- FOXO4-DRI as having human safety data
- "Anti-aging stacks" combining 4–5 injectable peptides without controlled-trial support
- Use as substitute for the interventions that DO have aging-relevant evidence: caloric balance, resistance training, sleep, blood-pressure control, lipid management, smoking cessation
Practical considerations
The anti-aging peptide space has the worst signal-to-noise ratio of any application area. The strongest aging-relevant evidence in medicine generally is unrelated to peptides — exercise, nutrition, blood pressure control, blood lipid management, sleep, social engagement. Peptide use should not displace these.
Where to source
- GHK-Cu vendor rankings — 14 ranked vendors (topical formulations; cosmetic-grade quality varies)
- Sermorelin vendor rankings — limited
- MOTS-c vendor rankings — limited; lower independent testing volume
- Tesamorelin vendor rankings — regulatorily constrained
Epitalon and FOXO4-DRI have minimal independent third-party testing data; vendor selection here is mostly an act of faith.
What we don't know
- Whether any peptide produces lifespan extension in any controlled human study (the answer to date is "no peptide has been tested for this")
- Whether MOTS-c will mature beyond mitochondrial-research curiosity
- Whether tesamorelin's visceral-fat selectivity has long-term mortality implications outside HIV populations
- Almost everything else in this space
Methodology
Read the full methodology.
This page is educational. The "best peptides for anti-aging" framing reflects what the market discusses, not what the evidence supports. Set expectations accordingly.